Introduction

Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, are widely used as cholesterollowering medicines for the prevention of cardiovascular disease. Moreover, statins have recently been shown to exert pleiotropic effects on various cells, which may not be directly related to cholesterol synthesis. Basic studies have shown that statins affect bone, by inducing bone morphogenetic protein-2 (BMP-2) and endothelial nitric oxide synthase (eNOS) expression in osteoblasts and by stimulating bone formation (1, 2). In addition, some studies have demonstrated that statins inhibit bone resorption by directly inhibiting the mevalonate pathway in osteoclasts (3). In contrast, several clinical studies investigating the effects of statins on bone present controversial results (4-10). Rosuvastatin is a relatively new product with powerful lipidlowering potency. Previous in vitro and in vivo studies have shown that rosuvastatin inhibited bone resorption and recovered ovariectomy-induced bone loss
. However, to our knowledge, there is no report which examined the effects of rosuvastatin on bone metabolism in humans.
Ezetimibe, a specific inhibitor of cholesterol absorption, is widely used for the treatment of dyslipidemia as monotherapy or given with a statin (12 
Biochemical measurements
After overnight fasting, serum and urine were collected. Biochemical markers were measured by standard biochemical methods, as previously described (13, 14 
Correlations between changes in bone markers versus baseline characteristics
Correlations between the changes in bone turnover markers versus baseline characteristics including serum lipids levels were analyzed in all subjects (Table 2), however, no significant correlation was found. We also found no significant correlation when each group was analyzed separately (data not shown).
Correlations between the changes in bone markers versus changes in serum cholesterol levels (Table 3) , although no significant correlation was found between them. We also found no significant correlation when each group was analyzed separately (data not shown).
Next, we analyzed correlations between the changes in bone turnover markers versus changes in levels of total cholesterol and LDL cholesterol in all subjects
Discussion
In this study, serum osteocalcin levels were significantly increased at 3 T a b l e 1 . B a s e l i n e Ch a r a c t e r i s t i c s a n d Ch r o n o l o g i c a l Ch a n g e s i n Ma r k e r s f o r L i p i d a n d B o n (4, 5) and bone resorption markers decrease (5, 6) , while others showed negative results (7, 8) . Moreover, higher bone mineral density (5) and lower fracture rates (5, 9) Previous studies including ours indicated that hyperglycemia induces a low turnover of bone with osteoblast dysfunction and suppresses serum osteocalcin levels (14, (21) (22) (23) (24, 25) . Fernandez-Real et al have demonstrated that serum osteocalcin levels are associated with insulin sensitivity and insulin secretion in non-diabetic subjects (26) . We have recently shown that the serum osteocalcin level is associated with serum levels of HbA1c and total adiponectin, fat mass, and atherosclerosis parameters in diabetic patients (27) T a b l e 3 . Co r r e l a t i o n s b e t we e n Ch a n g e s i n B o n e Ma r k e r s Ve r s u s Ch a n g e s i n S e r u m L i p i d s 
T a b l e 2 . Co r r e l a t i o n s b e t we e n Ch a n g e s i n B o n e Ma r k e r s Ve r s u s B a s e l i n e Ch a r a c t e r i s t i c s
